European regulators are reviewing AstraZeneca’s application to market Tagrisso for the first-line treatment of adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have EGFR mutations.
Read More
AstraZeneca has signed a deal with US group G1 Therapeutics to test the potential of a new combination therapy for lung cancer.
Read More
European regulators have now issued a full approval for AstraZeneca’s lung cancer drug Tagrisso, having awarded the drug a conditional approval in February last year.
Read More
US regulators have issued a full approval of AstraZeneca’s lung cancer drug Tagrisso on the back of a strong progression-free survival (PFS) benefit observed in a late-stage trial.
Read More
